Mizuho Upgrades Solventum (SOLV), Cites Optimistic Dental Outlook, Acera Acquisition

SOLV -0.06%

Solventum Corporation (NYSE:SOLV) is one of the most profitable new stocks to buy right now. On January 20, Mizuho upgraded Solventum from Neutral to Outperform, raising its price target to $100 from $85. The firm’s decision is supported by its annual dental industry survey, which revealed a more optimistic outlook for consumables and patient volumes compared to previous years. Additionally, the upgrade reflects higher valuation estimates following Solventum’s acquisition of Acera.

On January 7, Stifel raised its price target for Solventum to $105 from $88 and maintained a Buy rating. The firm believes that the outlook for large-cap MedTech in 2026 is favorable following the pressures faced in 2025.

On December 23, Solventum Corporation (NYSE:SOLV) finalized its acquisition of Acera Surgical, which is a bioscience company that specializes in synthetic tissue matrices for regenerative wound care, for an upfront cash payment of $725 million. The deal, which includes up to $125 million in additional milestone-based payments, is designed to enhance Solventum’s MedSurg portfolio in US acute care settings. While the transaction is expected to be slightly dilutive to adjusted EPS in 2026, it is projected to become accretive starting in 2027.

15 States with the Best Healthcare in the US

Solventum Corporation (NYSE:SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the US and internationally. It has three segments: Medsurg, Dental Solutions, and Health Information Systems.

While we acknowledge the potential of SOLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.